Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cerebrospinal fluid NPTX2/p-tau ratio as a biomarker for cognitive decline in neurodegenerative diseases.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old.

Neurology·2026
Same author

Naming performance in bilinguals with Alzheimer's disease and mild cognitive impairment.

Journal of Alzheimer's disease : JAD·2026
Same author

Peak width of skeletonized mean diffusivity reveals early and multifactorial white matter injury across sporadic and Down syndrome-associated Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.

Neurologia·2026
Same author

Characterizing circadian rest-activity rhythm patterns across Alzheimer's disease continuum in Down syndrome.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Judit Selma-Gonzalez1,2, Sara Rubio-Guerra1,2, Jesús Garcia Castro2,3

  • 1Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

化在氨酸217 (p-tau217) 的化预测了阿尔茨海默病 (AD) 的进展. 较高的血p-tau217水平表明认知和功能衰退的速度更快,表明其在阿尔茨海默病的预后效用.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物研究 生物标志物研究
  • 临床神经学 临床神经学

背景情况:

  • 化陶在氨酸217 (p-tau217) 是针对阿尔茨海默病 (AD) 病理学的特定血液生物标志物.
  • 现有的研究证实了高诊断准确度和可重复的血p-tau217.7的切断值.
  • 血p-tau217在不同AD临床阶段的预后值需要进一步调查.

研究的目的:

  • 评估血p-tau217在预测临床和功能衰退方面的预后效益.
  • 评估血p-tau217在阿尔茨海默病临床阶段的全谱中的预测能力.
  • 分析与AD病理状态相关的血p-tau217的纵向变化.

主要方法:

  • 一项对731名参与者的队列研究 (神经退行症圣保罗倡议 - SPIN队列),随访时间长达10年.
  • 根据CSFAD病理标志物 (p-tau181/Aβ1-42比率) 将参与者分为1-6临床阶段.
  • 使用ALZpath pTau217试验测量了血p-tau217度;通过MMSE评估认知/功能下降,并进展到第4阶段.

主要成果:

  • 血p-tau217水平随着AD病理病理的个体的临床阶段的推进而增加.
  • 血p-tau217和脑液p-tau181都与认知指标相关,并预测了更快的认知衰退.
  • 较高的血p-tau217水平与较慢的认知/功能衰退有关,并独立预测非痴呆症患者的痴呆症进展加速.

结论:

  • 血p-tau217,通过商业免疫测试测量,与AD的认知和功能下降有关.
  • 这些发现支持血p-tau217在常规临床实践中用于监测和预测AD进展的潜在使用.
  • 血p-tau217证明了在AD临床阶段的预后效用,补充了其诊断价值.